Samuel Brusca, MD
Cardiovascular Disease (Cardiology) · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
- Since medical school
- 12 years
- New York University School of Medicine, 2014
Offices
2 locations · Regents of the University of California · University of California San Francisco
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Brusca’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A168461 · Current
Licensed to practise in California · since 2020 · expires 2028-04-30 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Critical Care Medicine
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$104,487
Medicare paid this office $104,487 for 220 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 132 | $70,482 | $182 |
| Critical care, each additional 30 minutes | 56 | $12,530 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $3,785 | $105 |
| Long return visit (40+ min) | 20 | $3,759 | $125 |
| New patient visit (60+ min) | 15 | $1,972 | $131 |
See all 10 services
| Critical care, first 30-74 minutes | 132 | $70,482 | $182 |
| Critical care, each additional 30 minutes | 56 | $12,530 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $3,785 | $105 |
| Long return visit (40+ min) | 20 | $3,759 | $125 |
| New patient visit (60+ min) | 15 | $1,972 | $131 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 18 | $1,315 | $69 |
| Insertion of tube in pulmonary artery for monitoring | 14 | $1,030 | $74 |
| Insertion of artery tube for blood sampling or infusion through skin | 24 | $970 | $37 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | $727 | $27 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 32 | $698 | $14 |
Procedures Medicare counted
| Pacemaker insertion or repair | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Insertion of artery tube for blood sampling or infusion through skin | – | – | – | 17 | 26 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | – | – | – | 15 | 19 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
220 Original Medicare patients in 2024. Average age 71 · Under 65 20% · 85 and older 10% · Women 40% · Also on Medicaid 51% · Health risk score 3.34. Sicker patients than 9 in 10 peers; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Heart failure 75% · Chronic kidney disease 70% · Coronary heart disease 69% · Atrial fibrillation 62% · Diabetes 54% · COPD 38% · Depression 33% · Stroke 29% · Cancer 16% · Dementia 15%.
The office billed $854,637, Medicare allowed $132,823 and paid $104,487; for 810 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 220 | 810 | 71 | 3.34 | $854,637 | $104,487 |
| 2023 | 140 | 552 | 72 | 2.97 | $712,021 | $85,846 |
| 2022 | 36 | 97 | 69 | 2.22 | $105,823 | $13,495 |
| 2020 | 27 | 41 | 79 | 2.36 | $21,044 | $6,832 |
| 2019 | 38 | 51 | 76 | 2.77 | $26,640 | $8,722 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Critical care, first 30-74 minutes | 102 | $68,738 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $3,691 | $103 |
| Critical care, each additional 30 minutes | 15 | $2,229 | $93 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 12 | $1,073 | $72 |
| Insertion of tube in pulmonary artery for monitoring | 11 | $817 | $74 |
| Insertion of artery tube for blood sampling or infusion through skin | 16 | $639 | $38 |
2022: 2 services
| Critical care, first 30-74 minutes | 20 | $9,038 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,511 | $90 |
2020: 1 service
| Critical care, first 30-74 minutes | 23 | $6,075 | $196 |
2019: 1 service
| Critical care, first 30-74 minutes | 34 | $7,570 | $194 |
Medicaid work
$60,065 in 2024
Medicaid paid $60,065 for 334 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 334 | $60,065 |
| 2024 | 334 | 1 | 20 | $60,065 |
| 2023 | 151 | 1 | 16 | $18,552 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 151 | $18,552 |
Drugs they prescribed that Part D paid
$561,528
Pharmacies billed $561,528 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 134) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
91 generic and 43 brand-name prescriptions · $561,528 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Uptravi | 12 | $315,550 | $26,296 |
| Jardiance | 11 | $16,382 | $1,489 |
| Tadalafil | 15 | $11,461 | $764 |
| Furosemide | 28 | $149 | $5 |
| Spironolactone | 27 | $124 | $5 |
See all 6 drugs
| Uptravi | 12 | $315,550 | $26,296 |
| Jardiance | 11 | $16,382 | $1,489 |
| Tadalafil | 15 | $11,461 | $764 |
| Furosemide | 28 | $149 | $5 |
| Spironolactone | 27 | $124 | $5 |
| Atorvastatin | 12 | $73 | $6 |
Year by year
| 2024 | 134 | 23 | 0% (0) | 32% | $561,528 |
| 2023 | 24 | None | 0% (0) | None | $4,753 |
| 2017 | 142 | 35 | None | None | $25,699 |
| 2016 | 543 | 83 | None | 21% | $49,635 |
| 2015 | 378 | 92 | 6% (21) | None | $49,970 |
| 2014 | 87 | 22 | None | None | $3,932 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Furosemide | 13 | $48 | $4 |
2017: 1 drug
| Amlodipine Besylate | 22 | $114 | $5 |
2016: 15 drugs
| Humalog Kwikpen U-100 | 12 | $5,685 | $474 |
| Atrovent Hfa | 12 | $3,586 | $299 |
| Metoprolol | 16 | $378 | $24 |
| Atorvastatin | 34 | $371 | $11 |
| Lidocaine-Prilocaine | 11 | $358 | $33 |
| Labetalol | 16 | $333 | $21 |
| Latanoprost | 13 | $255 | $20 |
| Pantoprazole | 27 | $236 | $9 |
| Lisinopril | 30 | $185 | $6 |
| Montelukast | 12 | $101 | $8 |
| Losartan | 14 | $95 | $7 |
| Ranitidine | 12 | $75 | $6 |
| Amlodipine Besylate | 20 | $68 | $3 |
| Furosemide | 22 | $63 | $3 |
| Fluticasone Propionate | 13 | $54 | $4 |
2015: 8 drugs
| Metoprolol | 12 | $392 | $33 |
| Oxycodone | 11 | $283 | $26 |
| Levothyroxine | 12 | $256 | $21 |
| Fluticasone Propionate | 17 | $214 | $13 |
| Lisinopril | 53 | $214 | $4 |
| Atorvastatin | 16 | $199 | $12 |
| Montelukast | 11 | $161 | $15 |
| Amlodipine Besylate | 18 | $94 | $5 |
2014: 1 drug
| Lisinopril | 13 | $84 | $6 |
Money from drug and device companies
$3,039 in 2025
| 2025 | 4 | 10 | $2,695 | $3,039 |
| 2024 | 1 | 1 | None | $125 |
| 2023 | 1 | 1 | None | $96 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Actelion Pharmaceuticals US | Uptravi | $2,817 | 5 payments
|
| Abiomed | None | $119 | 2 payments
|
| Merck Sharp & Dohme | None | $85 | 2 payments
|
| AngioDynamics | Alphavac | $17 | 1 payment
|
See all 10 published payments
| Abiomed | Meals · 2025-09-22 | None | $57 |
| Abiomed | Meals · 2025-09-16 | None | $62 |
| Merck Sharp & Dohme | Meals · 2025-05-21 | None | $41 |
| Actelion Pharmaceuticals US | Meals · 2025-05-17 | Uptravi | $55 |
| Actelion Pharmaceuticals US | Travel · 2025-05-17 | Uptravi | $23 |
| Actelion Pharmaceuticals US | Consulting · 2025-05-17 | Uptravi | $2,695 |
| Actelion Pharmaceuticals US | Meals · 2025-05-17 | Uptravi | $19 |
| Actelion Pharmaceuticals US | Travel · 2025-05-17 | Uptravi | $25 |
| AngioDynamics | Meals · 2025-05-09 | Alphavac | $17 |
| Merck Sharp & Dohme | Meals · 2025-03-30 | None | $44 |
See earlier years (2024, 2023)
2024: $125
| Actelion Pharmaceuticals US | None | $125 | 1 payment
|
2023: $96
| Merck Sharp & Dohme | None | $96 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Actelion Pharmaceuticals US, Inc. · Slp-C-23-USA-008-V01 · 2024 | Their institution | $138,228 |
| Actelion Pharmaceuticals US, Inc. · A Team-Based Patient Engagement Approach To Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension · 2025 | Their institution | $49,501 |
| Janssen Scientific Affairs, LLC · Slp-C-23-USA-008-V01 · 2024 | Their institution | $11,248 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1174942148
- Licence
- CA A168461California A168461: Current · expires 2028-04-30
- Trained
- New York University School of Medicine, 2014 · 12 years ago
- Group
- Regents of the University of California · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 505 Parnassus Ave Rm M1182a, San Francisco, CA, 94143
- NPI first listed
- 2014-04-07
- NPI last updated
- 2025-12-04
- NPI record certified
- 2025-12-04
This is when the NPI record was last certified, not a medical board exam.